Uffelman C.N., Chan N.I., Davis E.M., Wang Y., McGowan B.S., Campbell W.W. An Assessment of Mushroom Consumption on Cardiometabolic Disease Risk Factors and Morbidities in Humans: A Systematic Review. Nutrients. 2023;15(5):1079.
Rationale
"Mushrooms are heart-healthy" is a standard dietary claim; this systematic review asked what the human evidence actually shows across all cardiometabolic risk factors — lipids, glucose, blood pressure, inflammation, cardiovascular events.
Methods
A systematic review registered on PROSPERO (CRD42021214441), searching PubMed, CINAHL, Web of Science, Scopus and Cochrane (28 July 2021, updated 15 July 2022). Included 22 original human studies: 11 interventional and 11 observational, all on whole culinary mushrooms (predominantly button, oyster, shiitake) and cardiometabolic endpoints.
Results
Experimental data — limited — suggest reductions in triglycerides and hs-CRP, but no demonstrated effect on other lipids, glycemia or blood pressure. Observational data (7 of 11 studies using a-posteriori dietary assessments) did not confirm associations with total cholesterol, LDL, glucose, or cardiovascular morbidity and mortality. For other outcomes the evidence was conflicting or insufficient. Most included studies were rated "poor" quality on the NHLBI assessment tool.
Conclusions
The evidence for cardiometabolic benefit from eating mushrooms is thin: a plausible signal on triglycerides and inflammation, essentially nothing solid elsewhere — and study quality across the field is low.
Worth noting
This is the necessary corrective card in the catalog: an honest systematic review whose conclusion is mostly "the data are weak," not a validation of the healthy-heart slogan. Two specific signals (TG, hs-CRP) are the ones to watch — the rest is absence of evidence, which the review is careful to distinguish from evidence of absence. The NHLBI "poor" ratings across most of the field explain why confident claims elsewhere should be discounted.